Fortress Biotech (FBIO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FBIO Fortress Biotech

Watchlist

2.0300
-0.0200-0.98%

Close Aug 30 16:00 ET

2.0600
+0.0300+1.48%

Post 20:02 ET

46.31MMarket Cap-656P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Roth MKM Maintains Fortress Biotech(FBIO.US) With Buy Rating, Raises Target Price to $13
Moomoo NewsAug 15 03:31 ET · Ratings
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
Yahoo FinanceAug 13 17:15 ET
Fortress Biotech Q2 EPS $(0.73) Beats $(1.23) Estimate, Sales $14.90M Beat $14.77M Estimate
BenzingaAug 13 16:57 ET
10-Q: Q2 2024 Earnings Report
SEC announcementAug 13 16:36 ET · Announcements
Fortress Biotech: Q2 Earnings Snapshot
Yahoo FinanceAug 13 16:16 ET
Express News | Fortress Biotech Inc - Qtrly Shr Loss $0.73
ReutersAug 13 16:08 ET

Comments

Trytosaveabit

Jul 19 07:12

Update

$Fortress Biotech (FBIO.US)$ Fortress Biotech's Urica Therapeutics Entered Into An APA Royalty Agreement, Urica Sold The Rights To Its URAT1 Inhibitor Product Candidate In Development For The Treatment Of Gout, Dotinurad, And Related Intellectual Property, Licenses And Agreements To Crystalys Therapeutics In Return For Common Stock Equal To 35% Of Crystalys' Outstanding Equity
- SEC Filing

Trytosaveabit

May 15 15:17

Make a note

$Fortress Biotech (FBIO.US)$ Reuters· just
Fortress Biotech Inc: FDA Accepted Nda Filing for Dfd-29 to Treat Inflammatory Lesions & Erythema of Rosacea in Adults; Pdufa Goal Date of Nov 4, 2024

101539447

Apr 8 07:18

$Fortress Biotech (FBIO.US)$ even after good resilt thus share is going down. holding since last 3 months now.

carlton griffiths

Mar 25 01:50

$Fortress Biotech (FBIO.US)$ 👀 🤔

Moomoo AI

Mar 7 04:29

The low P/S ratio is likely due to investors' concerns about the company's poor revenue performance and underwhelming growth outlook. The company will need a significant change in fortune to justify a higher P/S ratio in the future.

Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Fly 29% But Investors Aren't Buying For Growth

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

FBIO Fortress Biotech

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target